

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)**

**Drug Safety and Risk Management Advisory Committee (DSaRM) Roster**

---

***Chairperson***

**Vincent Lo Re III, MD, MSCE**

Expertise: Infectious Diseases and  
Pharmacoepidemiology  
Term: 6/1/2021 – 5/31/2025  
Associate Professor of Medicine and Epidemiology  
Division of Infectious Diseases, Department of  
Medicine  
Division of Epidemiology, Department of  
Biostatistics, Epidemiology, and Informatics  
Center for Clinical Epidemiology and Biostatistics  
Perelman School of Medicine  
University of Pennsylvania  
836 Blockley Hall  
423 Guardian Drive  
Philadelphia, Pennsylvania 19104

**Maryann Amirshahi PharmD, MD, MPH, PhD,  
BCPS, FACMT, FACEP, FASAM, FCP**

Expertise: Emergency Medicine, Medical  
Toxicology, Addiction Medicine, Clinical  
Pharmacology  
Term: 10/31/2024 – 5/31/2028  
Professor of Emergency Medicine,  
Georgetown University School of Medicine  
Department of Emergency Medicine,  
MedStar Washington Hospital Center  
110 Irving Street NW  
Washington, District of Columbia 20010

**Sascha Dublin, MD, PhD**

Expertise: Internal Medicine,  
Pharmacoepidemiology  
Term: 6/1/2022 – 5/31/2026  
Senior Scientific Investigator  
Kaiser Permanente Washington Health Research  
Institute  
1730 Minor Avenue, Suite 1360  
Seattle, Washington 98101

**John B. Hertig, PharmD, MS, CPPS, FASHP**

Expertise: Medication Safety  
Term: 6/1/2021 – 5/31/2025  
Associate Professor  
Department of Pharmacy Practice  
Butler University College of Pharmacy and Health  
Sciences  
4600 Sunset Avenue  
Indianapolis, Indiana 46208

***Acting Designated Federal Officer***

**Michael Gu**

Division of Advisory Committee and Consultant  
Management  
Office of Executive Programs  
Center for Drug and Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, Maryland 20993-0002  
(301) 796-9001 Fax: (301) 847-8533  
E-mail: [DSaRM@fda.hhs.gov](mailto:DSaRM@fda.hhs.gov)

**Michael C. Dejos, PharmD, MBA, BCPS, CHOP,  
CPPS**

Expertise: Patient Safety, Pharmacovigilance,  
Continuous Improvement  
Term: 9/20/2023 – 5/31/2027  
System Medication Safety Officer  
Methodist Le Bonheur Healthcare  
Assistant Professor  
University of Tennessee Health Science Center  
1211 Union Avenue, Suite 640  
Memphis, Tennessee 38104

**James Floyd, MD, MS**

Expertise: Epidemiology, Internal Medicine  
Term: 6/1/2022 – 5/31/2026  
Co-Director, Cardiovascular Health Research Unit  
Professor of Medicine  
Adjunct Professor of Epidemiology  
University of Washington  
4333 Brooklyn Ave NE  
Seattle, Washington 98195

**Krista F. Huybrechts, MS, PhD**

Expertise: Pharmacoepidemiology  
Term: 6/1/2021 – 5/31/2025  
Associate Professor of Medicine and Epidemiology  
Harvard Medical School and Harvard T.H. Chan School  
of Public Health  
Division of Pharmacoepidemiology and  
Pharmacoeconomics  
Department of Medicine  
Brigham & Women's Hospital

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)**

**Drug Safety and Risk Management Advisory Committee (DSaRM) Roster (cont.)**

---

1620 Tremont Street, Suite 3030  
Boston, Massachusetts 02120

**Mara McAdams DeMarco, MS, PhD**

Expertise: Pharmacoepidemiology  
Term: 6/1/2021 – 5/31/2025  
Associate Professor  
Associate Vice Chair for Research  
Department of Surgery  
New York University  
1 Park Ave, 6-704  
New York, New York 10016

**Elizabeth Rebo, PharmD, MBA, CPPS**

Expertise: Medication Safety  
Term: 10/31/2024 – 5/31/2028  
Executive Director, Pharmacy Quality and Medication  
Safety  
National Pharmacy Services  
Kaiser Permanente  
12254 Bellflower Blvd  
Downey, California 90242

**\*\*Ignacio Rodriguez, MD**

Expertise: Drug Development, Clinical Safety and  
Risk Management  
Term: 6/11/2024 – 10/31/2027  
Vice President, Global Head Medical Safety  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, New Jersey 07936

**+Jens-Ulrich Stegmann, RN, MD**

Expertise: Clinical Development, Clinical Safety,  
Pharmacovigilance and Risk Management  
Term: 6/11/2024 – 10/31/2027  
Senior Vice President  
Global Head Clinical Safety and Pharmacovigilance, EU  
QPPV  
GlaxoSmithKline (GSK)  
20 Avenue Fleming  
Wavre, Belgium

---

**\* Consumer Representative (Vacant)**

**\*\* Industry Representative (non-voting)**

**+Alternate Industry Representative (non-voting)**

*Updated: November 7, 2024*